Ketotifen Fumarate and Salbutamol Sulphate Combined Transdermal Patch Formulations: In Vitro Release and Ex Vivo Permeation Studies

Overview

Journal Indian J Pharm Sci

Specialty Pharmacy

Date 2014 Jan 10

PMID 24403658

Citations 3

Authors

M Yousuf

M Ahmad

M Usman

I Ali

Affiliations

Soon will be listed here.

Abstract

The present work was performed to develop and evaluate transdermal patches of combined antiasthmatic drugs (salbutamol sulphate and ketotifen fumarate). Polyvinyl alcohol membrane was used as backing membrane and eudragit RL-100 was used as matrix material to suspend the drugs in the continuous thickness of the patch. Methanol was solvent and propylene glycol was used as plasticizer. Tween 20, isopropyl myristate, eucalyptus oil, castor oil and span-20 were used as permeability enhancers. Thickness, weight variation and drug uniformity were investigated. The patch formulations were also subjected to drug release in dissolution media and permeation through rabbit skin. Effects of different enhancers were evaluated on release and permeation of drugs. F3 formulations having isopropyl myristate as permeation enhancer, showed maximum amounts of drugs release (88.11% of salbutamol sulphate and 88.33% of ketotifen fumarate) at the end of 24 h dissolution study. F3 also showed maximum permeation of both drugs (4.235 mg salbutamol sulphate and 1.057 mg ketotifen fumarate) after 24 h permeation study through rabbit skin mounted in Franz cell. The patches having no enhancer in the formulation also showed some drug release and permeation due to the presence of plasticizer. The results of the study suggested that new controlled release transdermal formulations of combined antiasthmatic drugs can be suitably developed as an alternate to conventional dosage forms.

Citing Articles

Formulation development and evaluation, in silico PBPK modeling and in vivo pharmacodynamic studies of clozapine matrix type transdermal patches.

Qadir A, Jan S, Shoaib M, Sikandar M, Yousuf R, Ali F Sci Rep. 2025; 15(1):1204.

PMID: 39774012 PMC: 11707343. DOI: 10.1038/s41598-024-81918-6.

Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems.

Tsai H, Shih T, Tsai T, Hu J, Lai Y, Hsiao J Beilstein J Nanotechnol. 2024; 15:465-474.

PMID: 38711579 PMC: 11070952. DOI: 10.3762/bjnano.15.42.

Formulation and evaluation of transdermal drug delivery of topiramate.

Cherukuri S, Batchu U, Mandava K, Cherukuri V, Ganapuram K Int J Pharm Investig. 2017; 7(1):10-17.

PMID: 28405574 PMC: 5370344. DOI: 10.4103/jphi.JPHI_35_16.

References

Panchagnula R, Desu H, Jain A, Khandavilli S . Feasibility studies of dermal delivery of paclitaxel with binary combinations of ethanol and isopropyl myristate: role of solubility, partitioning and lipid bilayer perturbation. Farmaco. 2005; 60(11-12):894-9. DOI: 10.1016/j.farmac.2005.07.004. View

Devi V, Saisivam S, Maria G, Deepti P . Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev Ind Pharm. 2003; 29(5):495-503. DOI: 10.1081/ddc-120018638. View

Wang Y, Thakur R, Fan Q, Michniak B . Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm. 2005; 60(2):179-91. DOI: 10.1016/j.ejpb.2004.12.008. View

Mutalik S, Udupa N . Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004; 93(6):1577-94. DOI: 10.1002/jps.20058. View

Purdon C, Azzi C, Zhang J, Smith E, Maibach H . Penetration enhancement of transdermal delivery--current permutations and limitations. Crit Rev Ther Drug Carrier Syst. 2004; 21(2):97-132. DOI: 10.1615/critrevtherdrugcarriersyst.v21.i2.20. View

Kantarci G, Ozguney I, Karasulu H, Arzik S, Guneri T . Comparison of different water/oil microemulsions containing diclofenac sodium: preparation, characterization, release rate, and skin irritation studies. AAPS PharmSciTech. 2008; 8(4):E91. PMC: 2750677. DOI: 10.1208/pt0804091. View

Guy R . Current status and future prospects of transdermal drug delivery. Pharm Res. 1996; 13(12):1765-9. DOI: 10.1023/a:1016060403438. View

Mukherjee B, Mahapatra S, Gupta R, Patra B, Tiwari A, Arora P . A comparison between povidone-ethylcellulose and povidone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur J Pharm Biopharm. 2005; 59(3):475-83. DOI: 10.1016/j.ejpb.2004.09.009. View

Walters K, Walker M, OLEJNIK O . Non-ionic surfactant effects on hairless mouse skin permeability characteristics. J Pharm Pharmacol. 1988; 40(8):525-9. DOI: 10.1111/j.2042-7158.1988.tb05295.x. View

10.

Lugogo N, MacIntyre N . Life-threatening asthma: pathophysiology and management. Respir Care. 2008; 53(6):726-35. View

11.

Arora P, Mukherjee B . Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci. 2002; 91(9):2076-89. DOI: 10.1002/jps.10200. View

12.

Entwistle C, Rowe R . Plasticization of cellulose ethers used in the film coating of tablets. J Pharm Pharmacol. 1979; 31(5):269-72. DOI: 10.1111/j.2042-7158.1979.tb13499.x. View

13.

Murthy S, Hiremath S . Physical and chemical permeation enhancers in transdermal delivery of terbutaline sulphate. AAPS PharmSciTech. 2004; 2(1):E-TN1. PMC: 2750253. DOI: 10.1208/pt0201_tn1. View

14.

Jarjour N, Kelly E . Pathogenesis of asthma. Med Clin North Am. 2002; 86(5):925-36. DOI: 10.1016/s0025-7125(02)00087-1. View

15.

Trommer H, Neubert R . Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol. 2006; 19(2):106-21. DOI: 10.1159/000091978. View

16.

Vora B, Khopade A, Jain N . Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release. 1998; 54(2):149-65. DOI: 10.1016/s0168-3659(97)00100-4. View